<p>香港，2026 年 4 月 28 日 -（ACN Newswire）- 在全球生物制药技术持续创新、政策利好稳步推出以及临床需求不断上升的推动下，生物制药行业正迎来发展黄金周期。作为中国创新制药领域的代表企业，迈威生物（上海）有限公司（“迈威” 或 “公司”，股票代码：02493.HK）凭借其深厚的研发基础、整合的全产业链优势和前瞻性的全球布局，抓住了行业发展的机遇。今天，公司正式在香港证券交易所主板上市，加入香港股市的生物制药板块，开启国际发展的崭新篇章。</p>
<p>据报道，迈威成立于 2017 年，是国内领先的创新制药企业，拥有卓越的创新药物研发能力和从药物发现到商业销售的端到端全产业链能力。自成立以来，公司深耕肿瘤学、免疫学、眼科学和骨科等重大疾病的治疗领域，致力于为全球患者提供更安全、更高效的创新治疗方案。</p>
<p>丰富多样的产品管线构建核心竞争壁垒</p>
<p>丰富且前景广阔的产品组合是迈威稳步发展的核心支柱，也是其在市场上抢占先机的关键优势。公司在创新药物领域长期深耕，构建了涵盖多个类别和层次的多样化产品管线。截至目前，迈威拥有 4 个商业化产品和 10 个药物候选者：1 个处于新药申请阶段，1 个处于临床前阶段，覆盖多个高潜力治疗领域，支持长期增长。</p>
<p>迈威自主研发的核心产品 9MW2821 充分展示了公司在 ADC 领域的领先优势。9MW2821 是中国在临床开发进展方面最先进的针对 Nectin-4 的 ADC，位列全球重磅药物 Padcev 之后。同时，它也是全球首个进入关键 III 期临床试验的针对宫颈癌和三阴性乳腺癌的 Nectin-4 靶向 ADC，具有广泛的市场潜力。</p>
<p>除了 9MW2821，迈威还在持续推进针对其他新靶点的 ADC 候选药物的研发，并构建了全面的 ADC 管线组合。其管线包括 7MW3711，一种专门靶向 B7-H3（免疫检查点蛋白）的 ADC，以及 7MW4911，一种专门靶向 CDH17 的 ADC。这一布局进一步丰富了公司在肿瘤治疗领域的足迹，稳步巩固了其在 ADC 赛道的领先优势。</p>
<p>值得注意的是，迈威还战略性地优先布局了涵盖单克隆抗体（mAbs）、TCE 双特异性抗体、融合蛋白和小分子药物的产品管线，形成了多产品类别协调发展的格局。其研发组合包括：9MW3811，一种针对 IL-11 的人的单克隆抗体，用于治疗与纤维化相关的疾病和癌症；9MW1911，国内首个获得临床开发批准的针对 ST2 的药物候选者；9MW3011，一种重组人源化 TMPRSS6 靶向单克隆抗体，在全球开发状态中处于领先地位；以及 6MW5311，全球首个针对 LILRB4/CD3 的 TCE 双特异性抗体，已申请临床试验。这些候选药物不断拓展公司的创新药物研发边界。</p>
<p>卓越的商业化能力，扩展全球市场足迹</p>
<p>凭借其全面整合的产业链能力和前瞻性的商业化战略，迈威生物（上海）有限公司持续交付可观的商业化成果。2025 年，公司旗下的 Junmaikang 在印度尼西亚获得了市场批准，而 Mailisheng 和 Maiweijian 则在巴基斯坦获得了商业化批准，标志着其国际商业化努力的稳步进展。</p>
<p>自 2022 年以来，公司积极扩展海外合作，签署了多项具有里程碑意义的国际合作协议，并获得相应的收益分成安排。成功进入巴西、印度尼西亚、沙特阿拉伯及 “一带一路” 沿线国家等新兴市场，建立了广泛的全球商业网络。</p>
<p>在全球合作方面，迈威进一步深化了国际布局。2023 年 1 月，公司与 Disc Medicine 签署了 9MW3011 的独家许可协议，预计可获得高达 4.125 亿美元的预付款、里程碑付款和版税。2025 年 6 月，与 Calico Life Sciences 达成了 9MW3811 的独家许可协议，总潜在对价超过 6 亿美元，包括预付款、里程碑和版税。2025 年 10 月，公司与 Kalexo Bio 签署了针对一种新型双靶点 siRNA 候选药物的独家许可协议，进一步拓展了其国际市场合作的广度和深度。</p>
<p>强大的技术平台为创新驱动增长奠定坚实基础</p>
<p>强大的技术平台是迈威持续创新的核心引擎，也是构建差异化竞争优势的关键。公司深耕技术研发，建立了四项核心 ADC 技术，拥有自主知识产权，为创新药物的开发提供了有力支持。</p>
<p>其中，DARfinity 是一种自主开发的特定部位连接工艺，能够实现精确的药物分子连接；IDconnect 是一种优化设计的连接分子，增强了抗体与毒素之间连接的稳定性；Mtoxin 是一类基于喜树碱的新型毒性分子，作为抗体药物偶联物（ADC）中的 “弹头” 用于杀死靶细胞，提供更强的靶细胞杀伤效果；LysOnly 是一种创新结构，允许条件性释放毒素，有效提高了 ADC 药物的整体安全性和疗效。</p>
<p>这四项专有技术作为我们特定部位连接 ADC 开发平台的核心支柱，协同使公司能够开发出具有更好均匀性、稳定性、纯度以及卓越疗效和安全性特征的 ADC 产品。这显著提高了管线研发效率，能够快速响应临床和市场需求，并持续巩固公司在 ADC 领域的领先地位。</p>
<p>此外，迈威生物持续开发和升级其他核心技术平台，形成多技术协同发展的系统。这些平台包括集成的高效抗体发现平台和基于 T 细胞连接器（TCE）的双/三特异性抗体开发平台等。在这些平台上开发的基于 TCE 的双/三特异性抗体能够同时特异性结合肿瘤相关抗原和 T 细胞 CD3 表位，从而为公司在免疫治疗领域的战略定位奠定坚实的技术基础。</p>
<p>从行业角度来看，全球生物制药行业作为核心细分市场，近年来持续获得动力。全球肿瘤药物市场从 2019 年的 1435 亿美元增长到 2024 年的 2533 亿美元，年均增长率为 12.0%，预计到 2028 年和 2032 年将进一步增加到 3759 亿美元和 5482 亿美元，年均增长率分别为 2024 年至 2028 年的 10.4% 和 2028 年至 2032 年的 9.9%。这一趋势为像迈威生物这样的行业领先者提供了可观的增长机会，因其拥有核心技术和全球化布局。</p>
<p>在内部研发的推动下，依托于整个产业链的集成端到端能力，并在长期全球战略的指导下，迈威生物在创新制药领域持续稳步推进。凭借强大的产品管线、扎实的技术专长和成熟的商业化能力，公司建立了稳固的竞争地位。其在香港成功上市将进一步加速核心产品的发展，增强商业化战略，并强化核心竞争力。这反过来预计将使公司在生物制药浪潮中处于前沿，具备强大的长期增长潜力，值得市场密切关注。</p>
<p>版权 © 2026 ACN Newswire。保留所有权利。</p>

迈威生物-U

迈威生物-B

<p>迈威生物（上海）有限公司已于 2026 年 4 月 28 日在香港证券交易所主板正式上市。该公司成立于 2017 年，专注于创新药物，重点领域包括肿瘤学、免疫学及其他治疗领域。迈威生物拥有多样化的产品管线，包括 4 个商业化产品和 10 个药物候选者，在抗体药物偶联物（ADCs）方面取得了显著进展。该公司还通过战略合作伙伴关系和在多个国家的商业化努力扩大了其全球市场影响力</p>

<p>HONG KONG, Apr 28, 2026 - (ACN Newswire) - Driven by the continuous innovation in global biopharmaceutical technology, the steady rollout of favorable policies, and escalating clinical demands, the biopharmaceutical industry is ushering in a golden cycle of development. As a representative enterprise in China's innovative pharmaceutical sector, Mabwell (Shanghai) Bioscience Co., Ltd. ('Mabwell' or the 'Company', stock code: 02493.HK) has seized industry development opportunities by leveraging its profound R&amp;D foundation, integrated whole-industry-chain advantages, and forward-looking global layout. Today, it officially listed on the Main Board of the Hong Kong Stock Exchange (HKEX), joining the biopharmaceutical sector of the Hong Kong stock market and opening a brand-new chapter in its international development.</p>
<div class="lb-trans"><p>香港，2026 年 4 月 28 日 -（ACN Newswire）- 在全球生物制药技术持续创新、政策利好稳步推出以及临床需求不断上升的推动下，生物制药行业正迎来发展黄金周期。作为中国创新制药领域的代表企业，迈威生物（上海）有限公司（“迈威” 或 “公司”，股票代码：02493.HK）凭借其深厚的研发基础、整合的全产业链优势和前瞻性的全球布局，抓住了行业发展的机遇。今天，公司正式在香港证券交易所主板上市，加入香港股市的生物制药板块，开启国际发展的崭新篇章。</p>
</div><p>Reportedly, founded in 2017, Mabwell is a leading domestic innovative pharmaceutical enterprise, possessing premier innovative drug R&amp;D capabilities and end-to-end whole-industry-chain capabilities that span from drug discovery to commercial sales. Since its establishment, the Company has been deeply engaged in therapeutic areas for major diseases such as oncology, immunology, ophthalmology, and orthopedics, and is committed to providing safer and more efficient innovative treatment solutions for patients worldwide.</p>
<div class="lb-trans"><p>据报道，迈威成立于 2017 年，是国内领先的创新制药企业，拥有卓越的创新药物研发能力和从药物发现到商业销售的端到端全产业链能力。自成立以来，公司深耕肿瘤学、免疫学、眼科学和骨科等重大疾病的治疗领域，致力于为全球患者提供更安全、更高效的创新治疗方案。</p>
</div><p>Rich and Diversified Product Pipeline Builds Core Competitive Barriers</p>
<div class="lb-trans"><p>丰富多样的产品管线构建核心竞争壁垒</p>
</div><p>A rich and promising product portfolio serves as the core pillar for Mabwell's steady development, as well as its key advantage in seizing first-mover opportunities in the market. With a long-term, deep-rooted presence in the innovative drug sector, the Company has built a diversified product pipeline featuring multiple categories and tiers. As of now, Mabwell has 4 commercialized products and 10 drug candidates: 1 in NDA stage,, 1 in preclinical stages, covering multiple high-potential therapeutic areas and supporting long-term growth.</p>
<div class="lb-trans"><p>丰富且前景广阔的产品组合是迈威稳步发展的核心支柱，也是其在市场上抢占先机的关键优势。公司在创新药物领域长期深耕，构建了涵盖多个类别和层次的多样化产品管线。截至目前，迈威拥有 4 个商业化产品和 10 个药物候选者：1 个处于新药申请阶段，1 个处于临床前阶段，覆盖多个高潜力治疗领域，支持长期增长。</p>
</div><p>Mabwell's self-developed core product, 9MW2821, fully demonstrates the Company's leading edge in the ADC field. 9MW2821 is the most advanced among all Nectin-4-targeting ADCs for urothelial carcinoma ('UC') in China in terms of clinical development progress, and only second to the globally blockbuster drug Padcev. Meanwhile, it is also the first Nectin-4-targeting ADC globally to enter the pivotal Phase III clinical trials for cervical cancer ('CC'), and triple-negative breast cancer ('TNBC'), boasting extensive market potential.</p>
<div class="lb-trans"><p>迈威自主研发的核心产品 9MW2821 充分展示了公司在 ADC 领域的领先优势。9MW2821 是中国在临床开发进展方面最先进的针对 Nectin-4 的 ADC，位列全球重磅药物 Padcev 之后。同时，它也是全球首个进入关键 III 期临床试验的针对宫颈癌和三阴性乳腺癌的 Nectin-4 靶向 ADC，具有广泛的市场潜力。</p>
</div><p>Beyond 9MW2821, Mabwell continues to advance the R&amp;D of ADC candidates targeting other novel targets and has built a comprehensive ADC pipeline portfolio. Its pipeline includes 7MW3711, an ADC specifically targeting B7-H3 (an immune checkpoint protein), and 7MW4911, an ADC specifically targeting CDH17. This layout further diversifies the Company's footprint in oncology treatment and steadily consolidates its leading advantages in the ADC track.</p>
<div class="lb-trans"><p>除了 9MW2821，迈威还在持续推进针对其他新靶点的 ADC 候选药物的研发，并构建了全面的 ADC 管线组合。其管线包括 7MW3711，一种专门靶向 B7-H3（免疫检查点蛋白）的 ADC，以及 7MW4911，一种专门靶向 CDH17 的 ADC。这一布局进一步丰富了公司在肿瘤治疗领域的足迹，稳步巩固了其在 ADC 赛道的领先优势。</p>
</div><p>Notably, Mabwell has also strategically prioritized the layout of product pipelines covering monoclonal antibodies ('mAbs'), TCE bispecific antibodies, fusion proteins and small molecule drugs, fostering a pattern of coordinated development across multiple product categories. Its R&amp;D portfolio includes: 9MW3811, a humanized monoclonal antibody targeting IL-11 for the treatment of fibrosis -related diseases and cancers; 9MW1911, the first domestically developed drug candidate approved for clinical development in China targeting ST2; 9MW3011, a recombinant humanized TMPRSS6 targeting mAb among the leading TMPRSS6-targeting therapies in terms of development status globally; and 6MW5311, the world's first LILRB4/CD3-targeted TCE bispecific antibody filed for clinical trials. These candidates keep expanding the boundaries of the Company's innovative drug research and development.</p>
<div class="lb-trans"><p>值得注意的是，迈威还战略性地优先布局了涵盖单克隆抗体（mAbs）、TCE 双特异性抗体、融合蛋白和小分子药物的产品管线，形成了多产品类别协调发展的格局。其研发组合包括：9MW3811，一种针对 IL-11 的人的单克隆抗体，用于治疗与纤维化相关的疾病和癌症；9MW1911，国内首个获得临床开发批准的针对 ST2 的药物候选者；9MW3011，一种重组人源化 TMPRSS6 靶向单克隆抗体，在全球开发状态中处于领先地位；以及 6MW5311，全球首个针对 LILRB4/CD3 的 TCE 双特异性抗体，已申请临床试验。这些候选药物不断拓展公司的创新药物研发边界。</p>
</div><p>Outstanding commercialization capabilities, expanding a global market footprint</p>
<div class="lb-trans"><p>卓越的商业化能力，扩展全球市场足迹</p>
</div><p>Leveraging its fully integrated industry chain capabilities and forward-looking commercialization strategy, Mabwell (Shanghai) Bioscience Co., Ltd. has continued to deliver tangible commercialization outcomes. In 2025, the Company's Junmaikang' obtained marketing approval in Indonesia, while Mailisheng' and Maiweijian were approved for commercialization in Pakistan, marking steady progress in its international commercialization efforts.</p>
<div class="lb-trans"><p>凭借其全面整合的产业链能力和前瞻性的商业化战略，迈威生物（上海）有限公司持续交付可观的商业化成果。2025 年，公司旗下的 Junmaikang 在印度尼西亚获得了市场批准，而 Mailisheng 和 Maiweijian 则在巴基斯坦获得了商业化批准，标志着其国际商业化努力的稳步进展。</p>
</div><p>Since 2022, the Company has actively expanded overseas collaborations, entering into multiple landmark international partnership agreements and securing corresponding revenue-sharing arrangements. It has successfully penetrated emerging markets including Brazil, Indonesia, Saudi Arabia, and countries along the Belt and Road Initiative, establishing an extensive global commercial network.</p>
<div class="lb-trans"><p>自 2022 年以来，公司积极扩展海外合作，签署了多项具有里程碑意义的国际合作协议，并获得相应的收益分成安排。成功进入巴西、印度尼西亚、沙特阿拉伯及 “一带一路” 沿线国家等新兴市场，建立了广泛的全球商业网络。</p>
</div><p>In terms of global partnerships, Mabwell has further deepened its international presence. In January 2023, the Company entered into an exclusive licensing agreement with Disc Medicine for 9MW3011, under which it is entitled to receive up to US$412.5 million in upfront payments, milestone payments, and royalties. In June 2025, it reached an exclusive licensing agreement with Calico Life Sciences for 9MW3811, with total potential consideration exceeding US$600 million, including upfront, milestone, and royalty payments. In October 2025, the Company signed an exclusive licensing agreement with Kalexo Bio for a novel dual-target siRNA candidate drug, further expanding the breadth and depth of its international market collaborations.</p>
<div class="lb-trans"><p>在全球合作方面，迈威进一步深化了国际布局。2023 年 1 月，公司与 Disc Medicine 签署了 9MW3011 的独家许可协议，预计可获得高达 4.125 亿美元的预付款、里程碑付款和版税。2025 年 6 月，与 Calico Life Sciences 达成了 9MW3811 的独家许可协议，总潜在对价超过 6 亿美元，包括预付款、里程碑和版税。2025 年 10 月，公司与 Kalexo Bio 签署了针对一种新型双靶点 siRNA 候选药物的独家许可协议，进一步拓展了其国际市场合作的广度和深度。</p>
</div><p>Powerful Technology Platforms Lay a Solid Foundation for Innovation-Driven Growth</p>
<div class="lb-trans"><p>强大的技术平台为创新驱动增长奠定坚实基础</p>
</div><p>Powerful technology platforms serve as the core engine for sustained innovation at Mabwell, and are also pivotal to building differentiated competitive advantages. With deep commitment to technological R&amp;D, the Company has established four core ADC technologies for which we possess proprietary intellectual property rights, providing strong support for the development of innovative drugs.</p>
<div class="lb-trans"><p>强大的技术平台是迈威持续创新的核心引擎，也是构建差异化竞争优势的关键。公司深耕技术研发，建立了四项核心 ADC 技术，拥有自主知识产权，为创新药物的开发提供了有力支持。</p>
</div><p>Among these, DARfinity is a self-developed site-specific conjugation process that enables precise drug molecule conjugation; IDconnect is an optimized design of linker molecules that enhances the stability of the linkage between the antibody and toxins; Mtoxin is a class of camptothecin-based novel toxic molecules that are used as the 'warhead' in the ADC to kill the targeted cells, providing more potent target cell killing effects; LysOnly is an innovative structure that allows conditional release of toxins, effectively improving the overall safety and efficacy of ADC drugs.</p>
<div class="lb-trans"><p>其中，DARfinity 是一种自主开发的特定部位连接工艺，能够实现精确的药物分子连接；IDconnect 是一种优化设计的连接分子，增强了抗体与毒素之间连接的稳定性；Mtoxin 是一类基于喜树碱的新型毒性分子，作为抗体药物偶联物（ADC）中的 “弹头” 用于杀死靶细胞，提供更强的靶细胞杀伤效果；LysOnly 是一种创新结构，允许条件性释放毒素，有效提高了 ADC 药物的整体安全性和疗效。</p>
</div><p>These four proprietary technologies serve as the core pillars of our site-specific conjugation ADC development platform, synergistically enabling the Company to develop ADC products with better uniformity, stability, purity, and a superior efficacy and safety profile. This significantly improves pipeline R&amp;D efficiency, allows rapid response to clinical and market demands, and continuously consolidates the Company's leading position in the ADC field.</p>
<div class="lb-trans"><p>这四项专有技术作为我们特定部位连接 ADC 开发平台的核心支柱，协同使公司能够开发出具有更好均匀性、稳定性、纯度以及卓越疗效和安全性特征的 ADC 产品。这显著提高了管线研发效率，能够快速响应临床和市场需求，并持续巩固公司在 ADC 领域的领先地位。</p>
</div><p>In addition, Mabwell continues to develop and upgrade other core technology platforms, forming a multi-technology synergistic development system. These platforms include the integrated high-efficiency antibody discovery platform and the T-cell engager (TCE)-based bi/tri-specific antibody development platform, among others. The TCE-based bi/tri-specific antibodies developed on these platforms can simultaneously and specifically bind to tumor-associated antigens and the T-cell CD3 epitope, thereby laying a solid technical foundation for the Company's strategic positioning in the field of immunotherapy.</p>
<div class="lb-trans"><p>此外，迈威生物持续开发和升级其他核心技术平台，形成多技术协同发展的系统。这些平台包括集成的高效抗体发现平台和基于 T 细胞连接器（TCE）的双/三特异性抗体开发平台等。在这些平台上开发的基于 TCE 的双/三特异性抗体能够同时特异性结合肿瘤相关抗原和 T 细胞 CD3 表位，从而为公司在免疫治疗领域的战略定位奠定坚实的技术基础。</p>
</div><p>From an industry perspective, the global biopharmaceutical sector, as a core segment, has continued to gain momentum in recent years. The global oncology drug market grew from US$143.5 billion in 2019 to US$253.3 billion in 2024 with a CAGR of 12.0%, and is expected to further increase to US$375.9 billion, and US$548.2 billion in 2028, and 2032 respectively, with CAGRs of 10.4% from 2024 to 2028 and 9.9% from 2028 to 2032, respectively. This trend presents substantial growth opportunities for leading industry players like Mabwell, which possess core technologies and a globalized footprint.</p>
<div class="lb-trans"><p>从行业角度来看，全球生物制药行业作为核心细分市场，近年来持续获得动力。全球肿瘤药物市场从 2019 年的 1435 亿美元增长到 2024 年的 2533 亿美元，年均增长率为 12.0%，预计到 2028 年和 2032 年将进一步增加到 3759 亿美元和 5482 亿美元，年均增长率分别为 2024 年至 2028 年的 10.4% 和 2028 年至 2032 年的 9.9%。这一趋势为像迈威生物这样的行业领先者提供了可观的增长机会，因其拥有核心技术和全球化布局。</p>
</div><p>Driven by in-house R&amp;D, supported by integrated end-to-end capabilities across the entire industry chain, and guided by a long-term global strategy, Mabwell continues to advance steadily in the innovative pharmaceutical sector. Leveraging a robust product pipeline, strong technological expertise, and well-established commercialization capabilities, the Company has built a solid competitive position. Its successful listing in Hong Kong will further accelerate the development of its core products, enhance its commercialization strategy, and strengthen its core competitiveness. This, in turn, is expected to position the Company at the forefront of the biopharmaceutical wave, with strong long-term growth potential that merits close market attention.</p>
<div class="lb-trans"><p>在内部研发的推动下，依托于整个产业链的集成端到端能力，并在长期全球战略的指导下，迈威生物在创新制药领域持续稳步推进。凭借强大的产品管线、扎实的技术专长和成熟的商业化能力，公司建立了稳固的竞争地位。其在香港成功上市将进一步加速核心产品的发展，增强商业化战略，并强化核心竞争力。这反过来预计将使公司在生物制药浪潮中处于前沿，具备强大的长期增长潜力，值得市场密切关注。</p>
</div><p>Copyright 2026 ACN Newswire . All rights reserved.</p>
<div class="lb-trans"><p>版权 © 2026 ACN Newswire。保留所有权利。</p>
</div>

在管线的赋能和技术的锻造下，迈威生物成功在香港交易所主板上市